CD3- and CD4-Positive Plasmablastic Lymphoma: A Literature Review of Japanese Plasmablastic Lymphoma Cases

Suzuki, Yuhko; Yoshida, Tsutomu; Nakamura, Naoya; Kamata, Hirotoshi; Kotani, Shouko; Ohsaka, Manabu; Kajita, Sabine; Miyazaki, Kôji; Ohtani, S.; Nakayama, Meijin; Horie, Ryouichi; Hayakawa, Kazushige; Niitsu, Nozomi; Higashihara, Masaaki

doi:10.2169/internalmedicine.49.3164

Cited by 35 publications

(24 citation statements)

References 22 publications

(22 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Several types of B-cell lymphomas, such as DLBCL with chronic inflammation [3] and plasmablastic lymphoma [6,7], often show ATCME. EBV is considered to contribute to this phenomenon.…”

Section: Discussionmentioning

confidence: 99%

“…Aberrant T-cell marker expression (ATCME) has been reported in some B-cell lymphomas [3,4,5,6,7] based on the widespread use of FCM as an auxiliary method employed for the diagnosis of malignant lymphoma. The phenomenon is well known to occur in DLBCL together with chronic inflammation [3] such as in pyothorax-associated lymphoma [4,5], and plasmablastic lymphoma [6,7], both of which are often associated with Epstein-Barr virus (EBV) infection. It has been shown that EBV latent membrane protein-1 is responsible for the up- and downregulation of a variety of cell surface or cytoplasmic molecules, including Bcl-2 [8,9,10].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Incidence and Clinical Significance of Aberrant T-Cell Marker Expression on Diffuse Large B-Cell Lymphoma Cells

Suzuki¹,

Yoshida²,

Wang³

et al. 2013

Acta Haematol

Self Cite

View full text Add to dashboard Cite

Introduction: Aberrant expression of T-cell markers is occasionally observed in B-cell lymphomas. We conducted a retrospective study to establish its incidence and to determine its relationship with clinical features of patients with diffuse large B-cell lymphoma (DLBCL). Patients and Methods: We reviewed DLBCL patients diagnosed between January 2002 and April 2009. Patients fulfilled the following criteria: (1) age >18 years, (2) HIV negative, (3) B-cell lymphoma confirmed by restricted expression of surface immunoglobulin light chains by flow cytometry (FCM). Aberrant T-cell marker expression (ATCME) was defined as positivity for CD2, CD3, CD4, CD7, and/or CD8 on DLBCL cells by FCM. Phenotyping was also performed by immunohistochemistry (IHC). Patients were grouped according to positive or negative ATCME and their clinical features including survival were compared. Results: Of 150 patients, 11 (7.3%) showed ATCME; CD2 and CD7 were most often expressed. ATCME was less often detected and the signal was weaker using IHC. There were no statistically significant differences in clinical features between the two groups. Conclusions: FCM may be useful to detect ATCME in a small amount of lymphoma cells. The mechanism responsible for ATCME, and whether it contributes in any way to the pathogenesis of B-cell neoplastic transformation, requires clarification.

show abstract

“…Several types of B-cell lymphomas, such as DLBCL with chronic inflammation [3] and plasmablastic lymphoma [6,7], often show ATCME. EBV is considered to contribute to this phenomenon.…”

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Incidence and Clinical Significance of Aberrant T-Cell Marker Expression on Diffuse Large B-Cell Lymphoma Cells

Suzuki¹,

Yoshida²,

Wang³

et al. 2013

Acta Haematol

Self Cite

View full text Add to dashboard Cite

show abstract

“…The CD4 expression on the PBL cells was unexpected, but has been seen in other cases, as has recently been reviewed [17]. Moreover, in a recent publication Goto H et al [18] describes the establishment of a CD4-positive cell line from an HIV-patient with PEL making our finding less conspicuously unique.…”

Section: Discussionmentioning

confidence: 56%

Epstein Barr virus DNA analysis in blood predicts disease progression in a rare case of plasmablastic lymphoma with effusion

Friis

Åkerlund

Christensson

et al. 2013

Infect Agents Cancer

View full text Add to dashboard Cite

Background: In HIV-1-infected patients a long lasting CD4+ cell decline influences the host-EBV balance and thereby increases the risk for EBV related malignancies. In spite of a world-wide access to combination antiretroviral therapy (cART) there are still a considerable number of HIV-1-infected patients who will develop severe immunodeficiency. These undiagnosed HIV-1 infected patients, so called late testers, demonstrate an increased lymphoma risk, compared to patients diagnosed early. Consecutive individual screening for EBV DNA-load in late testers might be a useful predictor of emerging EBV-malignancy. Methods: Patient biopsies and ascites were analyzed morphologically, by immuncyto-histochemistry and in-situ hybridization. Viral DNA and RNA load were quantified by PCR. Cell lines from primary tumor and from ascites, were established in vitro and further analyzed.

show abstract

“…Other small B-cell lymphomas, such as FL, MZL, LPL, and MCL, express T-cell markers other than CD5 uncommonly [13, 17, 18], which is also consistent with our observations. As for large B-cell lymphomas, T-cell markers other than CD5 were expressed more frequently in immunocompromised patients, such as in lymphomas occurring in HIV-positive patients [14, 16], pyothorax-associated lymphomas [15, 19, 20], plasmablastic lymphomas [23, 24, 27, 29], and Epstein-Barr virus (EBV)-positive DLBCLs of the elderly [30], than in common DLBCL (Table 1). Most of these non-CD5-T-cell marker-positive large B-cell lymphomas were reported to express CD3 by IHC analysis.…”

Section: Discussionmentioning

confidence: 99%

Clinical and prognostic significance of aberrant T-cell marker expression in 225 cases ofde novodiffuse large B-cell lymphoma and 276 cases of other B-cell lymphomas

et al. 2017

View full text Add to dashboard Cite

Expression of T-cell markers, generally investigated for immunophenotyping of T-cell lymphomas, is also observed in several types of B-cell lymphomas, including diffuse large B-cell lymphoma (DLBCL). We previously reported that CD5 expression in DLBCL is an inferior prognostic factor in the era of rituximab. However, data regarding the frequencies, histological relevance, and prognostic importance of T-cell markers other than CD5 are currently unavailable. In the present study, we comprehensively evaluated the expression of T-cell markers (CD2, CD3, CD4, CD5, CD7, and CD8) in 501 B-cell lymphomas, including 225 DLBCLs, by flow cytometry and subsequent immunohistochemistry. T-cell markers other than CD5, such as CD2, CD4, CD7, and CD8, were expressed in 27 (5%) patients, and notably, all of these cases were classified as large B-cell lymphoma subtypes: 25 DLBCLs and 2 intravascular large B-cell lymphomas. CD5 and other T-cell markers were expressed in 15% (31/225) and 10% (25/225) of DLBCL cases, respectively. Five of them co-expressed CD5 and other T-cell markers. Retrospectively analyzing the prognostic relevance of T-cell markers in 169 patients with primary DLBCL treated with rituximab-based chemotherapy, we showed that only CD5 was a strong predictor of poor survival. This study provides information about the occurrence of T-cell markers other than CD5 in B-cell lymphomas, their frequent histological subtypes, and their prognostic significance in DLBCL. CD5 was reconfirmed as a negative prognostic marker in DLBCL patients receiving rituximab-inclusive chemotherapy, whereas T-cell markers other than CD5 were found to have no impact on clinicopathological and survival analyses.

show abstract

CD3- and CD4-Positive Plasmablastic Lymphoma: A Literature Review of Japanese Plasmablastic Lymphoma Cases

Cited by 35 publications

References 22 publications

Incidence and Clinical Significance of Aberrant T-Cell Marker Expression on Diffuse Large B-Cell Lymphoma Cells

Incidence and Clinical Significance of Aberrant T-Cell Marker Expression on Diffuse Large B-Cell Lymphoma Cells

Epstein Barr virus DNA analysis in blood predicts disease progression in a rare case of plasmablastic lymphoma with effusion

Clinical and prognostic significance of aberrant T-cell marker expression in 225 cases ofde novodiffuse large B-cell lymphoma and 276 cases of other B-cell lymphomas

Contact Info

Product

Resources

About